Checkmate CEO hits the exit as Art Krieg's crew struggles to warm investors to TLR9 strategy
Almost three years after picking up the baton from Art Krieg to help steer Checkmate’s TLR9 agonist deeper into the clinic, CEO Barry Labinger is out.
Alan Fuhrman, a board member and chairman of the audit committee, has stepped in to fill the interim president and CEO role, steadying the ship with his background in financial operations. A former board director at Loxo Oncology, Fuhrman has also been CFO at Amplyx, Mirna and Ambit.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.